Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 263 | 75 | 3 |
Full Text Views | 11 | 0 | 0 |
PDF Downloads | 9 | 0 | 0 |
Genotypic heterogeneity in the repetitive portion of the circumsporozoite (CS) protein of Plasmodium vivax has been reported from many P. vivax-endemic areas. The objective of this study was to determine if the VK210 and VK247 CS variants of P. vivax differed in their clearance rates following chloroquine (CQ) therapy. One hundred seventy-one cases of P. vivax infection occurring in patients presenting to a research treatment center in Thailand were analyzed. Finger-prick blood samples were collected for microscopy and spotted onto filter paper at presentation and on each of five days of observation through supervised CQ therapy. A portion of the CS gene was amplified from filter paper samples by the polymerase chain reaction (PCR) and genotyped by oligoprobes specific for the VK210 and VK247 CS repeat regions. The mean time to clear parasitemia as determined by thick blood smear was significantly longer for pure VK210 infections (51 hr; 95% confidence interval [CI] 47.4ā54, P = 0.006) and mixed infections (53 hr; 95% CI 49.2ā56.7, P = 0.0009) as compared with VK247 infections (44 hr; 95% CI 39.8ā47.9). Five patients matched for parasitemia, age, sex, and previous malaria experience were selected from each of the three genotype groups in the larger study for further analysis by quantitative PCR of P. vivax genotype-specific DNA during a treatment course. The mean time to clear parasite DNA, as determined by PCR, was significantly slower for VK210 parasites (65 hr; 95% CI 51ā79) than for VK247 parasites (47 hr; 95% CI 30ā63, P = 0.045). In patients with mixed infections, VK210 DNA also cleared more slowly (mean 66 hr; 95% CI 40ā93) than VK247 DNA (mean 35 hr; 95% CI 23ā47, P = 0.056). These results suggest that strain-variable responses to CQ may exist. Detection and quantification of P. vivax genotype-specific DNA from filter paper samples may be useful as a method to monitor response to chemotherapy in a field setting.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 263 | 75 | 3 |
Full Text Views | 11 | 0 | 0 |
PDF Downloads | 9 | 0 | 0 |